A detailed history of Jpmorgan Chase & CO transactions in Mirum Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 23,832 shares of MIRM stock, worth $964,004. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23,832
Previous 145,560 83.63%
Holding current value
$964,004
Previous $3.66 Million 77.74%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$23.57 - $34.85 $2.87 Million - $4.24 Million
-121,728 Reduced 83.63%
23,832 $814,000
Q1 2024

May 10, 2024

SELL
$24.92 - $30.02 $1.02 Million - $1.23 Million
-41,023 Reduced 21.99%
145,560 $3.66 Million
Q4 2023

Feb 12, 2024

BUY
$27.14 - $34.93 $2.36 Million - $3.03 Million
86,807 Added 87.0%
186,583 $5.51 Million
Q3 2023

Nov 14, 2023

BUY
$24.63 - $32.85 $1.51 Million - $2.01 Million
61,311 Added 159.39%
99,776 $3.15 Million
Q2 2023

Aug 11, 2023

BUY
$23.51 - $30.09 $570,399 - $730,043
24,262 Added 170.82%
38,465 $995,000
Q1 2023

May 18, 2023

BUY
$19.19 - $24.1 $270,521 - $339,737
14,097 Added 13299.06%
14,203 $341,000
Q1 2023

May 11, 2023

SELL
$19.19 - $24.1 $1.51 Million - $1.89 Million
-78,465 Reduced 99.87%
106 $2,000
Q4 2022

Feb 13, 2023

BUY
$17.59 - $23.83 $1.13 Million - $1.53 Million
64,388 Added 453.98%
78,571 $1.53 Million
Q3 2022

Nov 14, 2022

BUY
$19.98 - $29.44 $80,879 - $119,173
4,048 Added 39.94%
14,183 $299,000
Q2 2022

Aug 11, 2022

BUY
$18.42 - $27.5 $88,710 - $132,440
4,816 Added 90.54%
10,135 $197,000
Q1 2022

May 11, 2022

SELL
$15.5 - $23.93 $267,375 - $412,792
-17,250 Reduced 76.43%
5,319 $117,000
Q4 2021

Feb 10, 2022

BUY
$13.05 - $19.35 $33,577 - $49,787
2,573 Added 12.87%
22,569 $360,000
Q3 2021

Nov 12, 2021

BUY
$13.95 - $20.18 $278,944 - $403,519
19,996 New
19,996 $399,000

Others Institutions Holding MIRM

About Mirum Pharmaceuticals, Inc.


  • Ticker MIRM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,751,700
  • Market Cap $1.49B
  • Description
  • Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...
More about MIRM
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.